| Chemical Properties | Back Directory | [Boiling point ]
643.0±55.0 °C(Predicted) | [density ]
1.301±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 100 mg/mL (222.04 mM; Need ultrasonic) | [form ]
Solid | [pka]
12.36±0.20(Predicted) | [color ]
Off-white to light yellow | [InChI]
InChI=1S/C22H25Cl2N3O3/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20/h3-7,14H,1-2,8-13,15H2,(H,25,28) | [InChIKey]
PMKMNTBZJOXTJW-UHFFFAOYSA-N | [SMILES]
O1C2=CC=C(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)C=C2NC(=O)C1 |
| Hazard Information | Back Directory | [Uses]
Brilaroxazine was developed as a antipsychotic which may be effective in the treatment of schizophrenia and bipolar disorder. | [in vivo]
Brilaroxazine (oral gavage; 10 mg/kg; twice daily; 28 days) limits the functional and structural effects of pulmonary arterial hypertension (PAH), with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO2, and pulmonary blood vessel structural changes[1]. | Animal Model: | SD-rats[2] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage; twice daily; 28 days | | Result: | Had the efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH. |
| [IC 50]
5-HT1A Receptor: 1.5 nM (Ki); 5-HT2A Receptor: 2.5 nM (Ki); 5-HT2B Receptor: 0.19 nM (Ki); 5-HT7 Receptor: 2.7 nM (Ki); D2 Receptor; D3 Receptor; D4 Receptor |
|
|